MIPS - Quality Measures - KRAS Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy

Quality Measures
Category QUALITY
Description Percentage of adult patients (aged 18 or over) with metastatic colorectal cancer who receive anti-epidermal growth factor receptor monoclonal antibody therapy for whom KRAS gene mutation testing was performed
eMeasure ID
First Performance Year 2017
Last Performance Year
Metric Type Single Performance Rate
National Quality Strategy Domain ECC
Measure Type Process
eMeasure UUID
NQF eMeasure ID
NQF ID 1859
Is High Priority?
Is Inverse?
Overall Algorithm
Primary Steward American Society of Clinical Oncology
Submission Methods Registry
Eligibility Options
Performance Options
Is Risk Adjusted?
Vendor ID
Is Registry Measure?
Registry Measure Spec
Web Interface Measure Spec
Claims Measure Spec

Back to List